Teva Pharmaceutical Industries Limited (TEVA) Position Lifted by Psagot Investment House Ltd.

Psagot Investment House Ltd. boosted its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 311.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 657,092 shares of the company’s stock after buying an additional 497,237 shares during the period. Psagot Investment House Ltd. owned approximately 0.06% of Teva Pharmaceutical Industries Limited worth $21,829,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of TEVA. Greylin Investment Mangement Inc. grew its stake in Teva Pharmaceutical Industries Limited by 36.9% in the second quarter. Greylin Investment Mangement Inc. now owns 294,495 shares of the company’s stock valued at $9,783,000 after purchasing an additional 79,300 shares in the last quarter. Financial Counselors Inc. grew its stake in Teva Pharmaceutical Industries Limited by 5.7% in the second quarter. Financial Counselors Inc. now owns 140,599 shares of the company’s stock valued at $4,671,000 after purchasing an additional 7,571 shares in the last quarter. PGGM Investments grew its stake in Teva Pharmaceutical Industries Limited by 12.0% in the second quarter. PGGM Investments now owns 1,528,097 shares of the company’s stock valued at $50,763,000 after purchasing an additional 163,292 shares in the last quarter. GAM Holding AG grew its stake in Teva Pharmaceutical Industries Limited by 23.2% in the second quarter. GAM Holding AG now owns 41,900 shares of the company’s stock valued at $1,392,000 after purchasing an additional 7,900 shares in the last quarter. Finally, Chou Associates Management Inc. grew its stake in Teva Pharmaceutical Industries Limited by 134.9% in the second quarter. Chou Associates Management Inc. now owns 505,000 shares of the company’s stock valued at $16,839,000 after purchasing an additional 290,000 shares in the last quarter. 56.75% of the stock is currently owned by hedge funds and other institutional investors.

Several research firms have recently issued reports on TEVA. BidaskClub upgraded Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating in a research note on Wednesday, July 5th. Vetr downgraded Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating and set a $32.27 price target for the company. in a research note on Tuesday, July 4th. Wells Fargo & Company reiterated a “hold” rating on shares of Teva Pharmaceutical Industries Limited in a research note on Tuesday, June 27th. Jefferies Group LLC reiterated a “hold” rating and set a $33.00 price target on shares of Teva Pharmaceutical Industries Limited in a research note on Friday, June 23rd. Finally, Cantor Fitzgerald set a $31.00 price target on Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a research note on Thursday, June 22nd. Five analysts have rated the stock with a sell rating, eighteen have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Teva Pharmaceutical Industries Limited presently has an average rating of “Hold” and an average price target of $27.63.

WARNING: “Teva Pharmaceutical Industries Limited (TEVA) Position Lifted by Psagot Investment House Ltd.” was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another domain, it was illegally copied and republished in violation of international trademark & copyright law. The legal version of this article can be accessed at https://sportsperspectives.com/2017/10/11/teva-pharmaceutical-industries-limited-teva-position-lifted-by-psagot-investment-house-ltd.html.

Teva Pharmaceutical Industries Limited (NYSE TEVA) traded down 0.38% during midday trading on Wednesday, reaching $15.83. The company had a trading volume of 3,742,459 shares. The stock’s 50 day moving average is $16.83 and its 200 day moving average is $26.44. Teva Pharmaceutical Industries Limited has a one year low of $15.22 and a one year high of $45.14. The company has a market capitalization of $16.07 billion, a PE ratio of 3.08 and a beta of 0.57.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing the consensus estimate of $1.06 by ($0.07). Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The firm had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. During the same quarter in the prior year, the firm earned $1.25 earnings per share. The firm’s revenue for the quarter was up 12.9% on a year-over-year basis. Equities research analysts forecast that Teva Pharmaceutical Industries Limited will post $4.26 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th were given a dividend of $0.085 per share. The ex-dividend date was Friday, August 25th. This represents a $0.34 annualized dividend and a yield of 2.14%. Teva Pharmaceutical Industries Limited’s dividend payout ratio is currently -15.36%.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply